Corporate Information-arkiv - Page 13 of 20

Isofol’s CEO Ulf Jungnelius has subscribed for all warrants

GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that […]

A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that

AGENT study update with regards to COVID-19

GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), informs that the

Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

GOTHENBURG, Sweden, May 29, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the

Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States

GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced approval

Information in relation to COVID-19

GOTHENBURG, Sweden, April 2, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has since the

Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin

GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that

Corporate Information